When TIDE analyses were conducted based on levels of these CNVs, patients with metastatic melanoma, GBM, and BRCA exhibiting high PSME2 CNV levels exhibited higher survival rates, whereas the opposite was true in papillary KIRC (Figure 3C). This evidence concerns the gene PSME2 and glioblastoma.